ImageneBio (NASDAQ:IMA) Trading 1.8% Higher - What's Next?

Key Points

• ImageneBio shares rose 1.8% to $5.68 in midday trading, although volume was 26% below the average session level.
• Analyst sentiment remains mixed but leans cautious: the stock has a consensus “Hold” rating, with a $30.00 average target price, while recent firms maintained or downgraded it to sell or underperform.
• The clinical-stage biotech reported a quarterly loss of $0.63 per share, beating the $0.90 loss expected by analysts. Institutional investors own approximately 75% of the company.

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) traded up 1.8% on Tuesday . The stock traded as high as $5.74 and last traded at $5.68. Approximately 7,345 shares were traded during mid-day trading, a decline of 26% from the average session volume of 9,902 shares. The stock had previously closed at $5.58.

Analyst Ratings Changes

A number of research analysts recently commented on IMA shares. Wall Street Zen cut ImageneBio from a "sell" rating to a "strong sell" rating in a research report on Sunday, May 17th. Weiss Ratings reiterated a "sell (e+)" rating on shares of ImageneBio in a research note on Monday, June 29th. Finally, Wedbush reissued an "underperform" rating on shares of ImageneBio in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $30.00.

ImageneBio Stock Performance

The stock has a fifty day simple moving average of $5.79 and a two-hundred day simple moving average of $5.89. The stock has a market cap of $64.47 million, a price-to-earnings ratio of -1.24 and a beta of 0.76.

ImageneBio (NASDAQ:IMA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.27. Equities analysts expect that ImageneBio, Inc. will post -3.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its position in ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company's stock worth $74,000 after purchasing an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of ImageneBio during the 4th quarter valued at $76,000. Millennium Management LLC acquired a new stake in shares of ImageneBio during the 4th quarter valued at $79,000. Bridgeway Capital Management LLC bought a new stake in ImageneBio during the 3rd quarter worth $104,000. Finally, NewEdge Advisors LLC bought a new stake in ImageneBio during the 3rd quarter worth $106,000. Institutional investors own 75.00% of the company's stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source